Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00XPA
|
||||
| Former ID |
DCL000857
|
||||
| Drug Name |
L-759274
|
||||
| Indication | Severe mood disorders; Depression [ICD9: 296, 311; ICD10:F30-F39, F32] | Discontinued in Phase 3 | [1] | ||
| Company |
Merck
|
||||
| CAS Number |
CAS 737803-81-5
|
||||
| Target and Pathway | |||||
| Target(s) | Substance-P receptor | Target Info | Antagonist | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Measles | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Reactome | G alpha (q) signalling events | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Spinal Cord Injury | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.